Drug - Sirturo™ [Janssen]
Therapeutic Area - Antituberculosis agents
Treatment is limited to 24 weeks of therapy.
SIRTURO™ is a diarylquinoline antimycobacterial drug indicated as part of combination therapy in adults (≥ 18 years) with pulmonary multi-drug resistant tuberculosis (MDR-TB). Reserve SIRTURO™ for use when an effective treatment regimen cannot otherwise be provided. SIRTURO™ is not indicated for the treatment of latent, extra-pulmonary or drug-sensitive tuberculosis or for the treatment of infections caused by non-tuberculous mycobacteria.
MHCP Provider Call Center 651-431-2700 or 800-366-5411